COVID-19疫苗安全监测首月:美国2020年12月14日至2021年1月13日
美国CDC对2020年12月14日至2021年1月13日期间接种的13,794,904剂COVID-19疫苗进行安全性监测,VAERS收到6,994份不良事件报告,其中90.8%为非严重事件,9.2%为严重事件。报告死亡113例,现有信息未提示与疫苗接种存在因果关系;两种疫苗过敏反应报告率为每百万剂4.5例。初步安全性特征未显示意外严重不良事件。
要点
- 首月接种13,794,904剂,VAERS报告6,994份不良事件,90.8%为非严重。
- 头痛(22.4%)、疲劳(16.5%)和头晕(16.5%)为最常报告症状。
- 过敏反应报告率为每百万剂4.5例,未发现意外严重不良事件信号。
核心结论
- 两种COVID-19疫苗初始授权后安全性特征未显示意外严重不良事件证据。
- 现有信息未提示疫苗接种与报告的死亡之间存在因果关系。
研究设计与样本
- CDC对2020年12月14日至2021年1月13日首月疫苗接种安全性数据开展描述性分析。
- 使用被动报告系统VAERS和主动监测系统v-safe收集不良事件信息。
主要发现
- 期间共接种13,794,904剂疫苗,VAERS收到并处理6,994份不良事件报告。
- 6,354份(90.8%)报告为非严重事件,640份(9.2%)为严重事件。
- VAERS最常报告症状为头痛(22.4%)、疲劳(16.5%)和头晕(16.5%)。
- VAERS报告113例死亡,其中78例(65%)为长期护理机构居民。
- 两种疫苗过敏反应报告率为每百万剂4.5例。
关键数值与推荐
- FDA于2020年12月11日对Pfizer-BioNTech COVID-19疫苗发布紧急使用授权,于12月18日对Moderna COVID-19疫苗发布紧急使用授权,均为2剂系列。
- ACIP于2020年12月12日和12月19日分别发布两种疫苗的临时推荐,初始剂量推荐用于医护人员和长期护理机构居民。
临床怎么用
- 接种后头痛、疲劳和头晕较常见,第二剂后反应可能更频繁,应告知接种者。
- 过敏反应虽罕见但需监测,报告率为每百万剂4.5例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Two coronavirus disease 2019 (COVID-19) vaccines are currently authorized for use in the United States. The Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine on December 11, 2020, and for the Moderna COVID-19 vaccine on December 18, 2020; each is administered as a 2-dose series. The Advisory Committee on Immunization Practices issued interim recommendations for Pfizer-BioNTech and Moderna COVID-19 vaccines on December 12, 2020 (1), and December 19, 2020 (2), respectively; initial doses were recommended for health care personnel and long-term care facility (LTCF) residents (3). Safety monitoring for these vaccines has been the most intense and comprehensive in U.S. history, using the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting system, and v-safe,* an active surveillance system, during the initial implementation phases of the COVID-19 national vaccination program (4). CDC conducted descriptive analyses of safety data from the first month of vaccination (December 14, 2020-January 13, 2021). During this period, 13,794,904 vaccine doses were administered, and VAERS received and processed† 6,994 reports of adverse events after vaccination, including 6,354 (90.8%) that were classified as nonserious and 640 (9.2%) as serious.§ The symptoms most frequently reported to VAERS were headache (22.4%), fatigue (16.5%), and dizziness (16.5%). A total of 113 deaths were reported to VAERS, including 78 (65%) among LTCF residents; available information from death certificates, autopsy reports, medical records, and clinical descriptions from VAERS reports and health care providers did not suggest any causal relationship between COVID-19 vaccination and death. Rare cases of anaphylaxis after receipt of both vaccines were reported (4.5 reported cases per million doses administered). Among persons who received Pfizer-BioNTech vaccine, reactions reported to the v-safe system were more frequent after receipt of the second dose than after the first. The initial postauthorization safety profiles of the two COVID-19 vaccines in current use did not indicate evidence of unexpected serious adverse events. These data provide reassurance and helpful information regarding what health care providers and vaccine recipients might expect after vaccination.
引用
- Gee J, Marquez P, Su J, et al. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33630816. doi:10.15585/mmwr.mm7008e3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。